Despite enormous research investment and effort immunity to malaria is still poorly understood. In general terms, the acute malaria infection is contained by non-specific host-defence mechanisms including splenic activation and fever (which inhibits schizogony). Later more specific humoral and cellular immunity control and finally eliminate the infection. After weeks of illness in untreated infections parasitaemia is eventually reduced to levels which are tolerated with few or no symptoms. Untreated malaria parasitaemia can persist at low densities for months or years [
98]. In malaria-endemic areas, where people are infected frequently, most infections are controlled at densities causing little or no symptoms, so some infections persist for weeks or months and many self- cure [
4]. Illness results from infections to which the individual has insufficient immunity to control parasite multiplication [
99]. In areas of higher transmission, this is most likely in young children who have had few or no previous infections. In older children and adults rapid mobilization of both non-specific and specific host-defence mechanisms usually results in prompt resolution of the infection—even without anti-malarial treatment. As a result “immunity” complements the effects of anti-malarial drugs, accelerating parasite clearance and augmenting cure rates [
100‐
103]. Failing drugs (i.e. anti-malarials to which resistance has developed) always perform much better in semi-immune patients. Acquired immunity explains why cure rates are always higher in adults and older children in endemic areas and why anti-malarial treatment efficacy assessments in high transmission settings should always include young children [
7]. The magnitude of the effect of immunity on parasite clearance can be assessed by comparing parasite clearance rates in drug sensitive infections with similar drug exposure between high transmission and low transmission areas [
32,
100], by assessing the effect of age on parasite clearance within an area of moderate or high transmission [
101], or directly by correlating parasite clearance rates with malaria antibody titres [
104]. In a recent large study the relationship of parasite clearance to titres of antibodies specific to 12
P. falciparum sporozoite and blood-stage antigens was assessed.
P. falciparum antibodies were associated with significantly faster PC
½ values but the effects were relatively small; maximum shortening <40 min [
104]. Immunity also reduces parasite multiplication (e.g. merozoite agglutinating antibodies) but this contributes relatively little to measures of immediate drug effect such as parasite clearance half-lives (PC
1/2). In the largest assessment to date the effect of age on parasite clearance following treatment with artemisinin derivatives was estimated in a subset of 3208 patients from areas without artemisinin resistance. Young children cleared parasites more slowly than older patients: PC
1/2 was 11.3% (95% CI 2.6–20.8, p = 0.010) longer in infants aged <1 year and 9.4% (95% CI 3.5–15.7, p = 0.002) longer in children aged 1–4 years compared to older patients. Overall PC
1/2 values were about 12 min faster in Africa than in Asia, where transmission is generally lower [
101].